Telesis Bio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Telesis Bio generated cash of -$34,667,000, which is more than the previous year. Cash used in financing activities reached the amount of $11,565,000 last year. Net change in cash is therefore -$28,849,000.
Cash Flow
| 2016 | -23.71M | 6.10M | 50.74M |
|---|---|---|---|
| 2017 | -50.78M | 304K | 41.74M |
| 2018 | -22.13M | -85.29M | 113.62M |
| 2019 | -6.39M | -79K | 35.10M |
| 2020 | -15.38M | -204K | -96K |
| 2021 | -36.69M | -15.04M | 121.08M |
| 2022 | -38.71M | -18.00M | 4.51M |
| 2023 | -34.66M | -5.74M | 11.56M |
TBIO Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 30.59M | 82.80M | 13.46M | 29.14M | 56.22M | 50.02M | 58.76M | 25.62M |
Operating activities | ||||||||
Net income | -47.72M | -48.47M | -38.95M | -18.01M | -8.30M | -97.39M | -66.44M | -26.69M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 4.10M | 2.87M | 1.57M | 1.45M | 857K | 2.84M | 1.58M | 730K |
Stock-based compensation expense | 3.96M | 3.72M | 1.08M | 43K | 13.2K | 0 | 3.68M | 686K |
| Deferred income tax benefit | 3.96M | 3.72M | 1.08M | 43K | 13.2K | 0 | 3.68M | 686K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -1.33M | -2.18M | -735K | -774K | -859K | 0 | 0 | 0 |
Inventories | -1.82M | 168K | -1.46M | 111K | 723K | 0 | 0 | 0 |
Accounts payable | -3.28M | 1.16M | -298K | 142K | 232K | 658K | 4.02M | 84K |
Cash generated by operating activities | -34.66M | -38.71M | -36.69M | -15.38M | -6.39M | -22.13M | -50.78M | -23.71M |
Investing activities | ||||||||
Purchases Of Investments | -33.77M | -77.42M | 0 | 0 | -174.27M | -136.69M | -70.76M | -34.93M |
Investments In Property Plant And Equipment | -1.98M | -4.46M | -1.85M | -204K | -79K | -6.58M | -2.76M | -862K |
Acquisitions Net | 0 | -556K | -13.18M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5.74M | -18.00M | -15.04M | -204K | -79K | -85.29M | 304K | 6.10M |
Financing activities | ||||||||
Common Stock Issued | 26.65M | 528K | 112.48M | 11K | 32.95M | 117.44M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -15.09M | 4.68M | -5.08M | -107K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 11.56M | 4.51M | 121.08M | -96K | 35.10M | 113.62M | 41.74M | 50.74M |
Net Change In Cash | -28.84M | -52.21M | 69.34M | -15.68M | -27.08M | 6.2M | -8.73M | 33.13M |
Cash at end of period | 1.74M | 30.59M | 82.80M | 13.46M | 29.14M | 56.22M | 50.02M | 58.76M |
| Data source | Data source |